{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:56:39Z","timestamp":1791849399313,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study was designed to identify genes for further study as modifiers of the severity of cardiomyopathy in\n                      <jats:italic>DMD-<\/jats:italic>\n                      related Duchenne Muscular Dystrophy (DMD).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated genome sequencing results in a well-phenotyped DMD cohort with severe cardiomyopathy against those with less severe cardiomyopathy. Using combined annotation-dependent depletion variant annotation to look at variant burden, we created a difference between group mean (DBGM) summative C-Scores by gene. We completed analyses on three groups. For each analysis, we normalized DBGM summative C-Score and determined which genes had a value &gt; three standard deviations from the mean in all three analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There were 54 DMD males in this analysis. 18 individuals (33%) had severe cardiomyopathy and 36 individuals (67%) had less severe cardiomyopathy. Nine genes were identified as possible cardiomyopathy severity modifiers:\n                      <jats:italic>ANKLE1<\/jats:italic>\n                      ,\n                      <jats:italic>ESRRA<\/jats:italic>\n                      ,\n                      <jats:italic>FRAS1<\/jats:italic>\n                      ,\n                      <jats:italic>GEMIN4<\/jats:italic>\n                      ,\n                      <jats:italic>GXYLT1<\/jats:italic>\n                      ,\n                      <jats:italic>MTCH2<\/jats:italic>\n                      ,\n                      <jats:italic>PKD1L2<\/jats:italic>\n                      ,\n                      <jats:italic>PRSS2<\/jats:italic>\n                      and\n                      <jats:italic>QRFPR<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      DBGM summative C-Scores in well-phenotyped groups are a feasible exploratory method to identify genetic targets for additional study. There is preliminary evidence from this and other studies suggesting further evaluation of\n                      <jats:italic>ESRRA<\/jats:italic>\n                      ,\n                      <jats:italic>GEMIN4<\/jats:italic>\n                      , and\n                      <jats:italic>MTCH2<\/jats:italic>\n                      as modifiers of cardiomyopathy severity could advance understanding of DMD cardiomyopathy progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This article identifies possible genetic modifiers of DMD cardiomyopathy severity via a novel method of looking at variant burden between groups. This adds to the existing literature by providing new evidence for modifier pathway targets for possible therapeutic targets or drug repurposing in a rare genetic disorder.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04683-w","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:23:14Z","timestamp":1767781394000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Variant burden and severity of cardiomyopathy in patients with DMD-related Duchenne muscular dystrophy"],"prefix":"10.1038","author":[{"given":"Gabrielle C.","family":"Geddes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Ware","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hwi","family":"Schwantes-An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner C.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan H.","family":"Soslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Markham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"4683_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.cardfail.2019.02.006","volume":"25","author":"JH Soslow","year":"2019","unstructured":"Soslow, J. H. et al. The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in Duchenne muscular dystrophy cardiomyopathy. J. Card. Fail. 25, 259\u2013267 (2019).","journal-title":"J. Card. Fail."},{"key":"4683_CR2","doi-asserted-by":"crossref","unstructured":"Willi, L. et al. Bioenergetic and metabolic impairments in induced pluripotent stem cell-derived cardiomyocytes generated from Duchenne muscular dystrophy patients. Int. J. Mol. Sci. 23, 9808 (2022).","DOI":"10.3390\/ijms23179808"},{"key":"4683_CR3","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","volume":"270","author":"M Chang","year":"2023","unstructured":"Chang, M. et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J. Neurol. 270, 3733\u20133749 (2023).","journal-title":"J. Neurol."},{"key":"4683_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010040","volume":"16","author":"JH Soslow","year":"2023","unstructured":"Soslow, J. H. et al. Cardiovascular measures of all-cause mortality in duchenne muscular dystrophy. Circ. Heart Fail. 16, e010040 (2023).","journal-title":"Circ. Heart Fail."},{"key":"4683_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1183101","volume":"14","author":"A Bez Batti Angulski","year":"2023","unstructured":"Bez Batti Angulski, A. et al. Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. Front. Physiol. 14, 1183101 (2023).","journal-title":"Front. Physiol."},{"key":"4683_CR6","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.amjcard.2015.01.030","volume":"115","author":"A Tandon","year":"2015","unstructured":"Tandon, A. et al. Dystrophin genotype-cardiac phenotype correlations in duchenne and becker muscular dystrophies using cardiac magnetic resonance imaging. Am. J. Cardiol. 115, 967\u2013971 (2015).","journal-title":"Am. J. Cardiol."},{"key":"4683_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.yjmcc.2020.05.006","volume":"144","author":"Y Chen","year":"2020","unstructured":"Chen, Y. et al. Identifying modifier genes for hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 144, 119\u2013126 (2020).","journal-title":"J. Mol. Cell Cardiol."},{"key":"4683_CR8","doi-asserted-by":"crossref","unstructured":"Glava\u0161ki, M., Velicki, L. & Vu\u010dini\u0107, N. Hypertrophic cardiomyopathy: genetic foundations, outcomes, interconnections, and their modifiers. Medicina 59, 1424 (2023).","DOI":"10.3390\/medicina59081424"},{"key":"4683_CR9","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1161\/CIRCULATIONAHA.120.050432","volume":"143","author":"AM Gacita","year":"2021","unstructured":"Gacita, A. M. et al. Genetic variation in enhancers modifies cardiomyopathy gene expression and progression. Circulation 143, 1302\u20131316 (2021).","journal-title":"Circulation"},{"key":"4683_CR10","doi-asserted-by":"crossref","unstructured":"Rahit, K. M. T. H. & Tarailo-Graovac, M. Genetic modifiers and rare Mendelian disease. Genes 11, 239 (2020).","DOI":"10.3390\/genes11030239"},{"key":"4683_CR11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.echo.2016.07.001","volume":"29","author":"JH Soslow","year":"2016","unstructured":"Soslow, J. H. et al. Evaluation of echocardiographic measures of left ventricular function in patients with duchenne muscular dystrophy: assessment of reproducibility and comparison to cardiac magnetic resonance imaging. J. Am. Soc. Echocardiogr. 29, 983\u2013991 (2016).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"4683_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3389\/fgene.2019.00736","volume":"10","author":"KI Kendig","year":"2019","unstructured":"Kendig, K. I. et al. Sentieon Dnaseq variant calling workflow demonstrates strong computational performance and accuracy. Front. Genet. 10, 736 (2019).","journal-title":"Front. Genet."},{"key":"4683_CR13","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"4683_CR14","unstructured":"Li, H. Vol. arXiv:1303.3997v1 [q-bio.GN] (2013)."},{"key":"4683_CR15","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ng.2892","volume":"46","author":"M Kircher","year":"2014","unstructured":"Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46, 310\u2013315 (2014).","journal-title":"Nat. Genet."},{"key":"4683_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00835-9","volume":"13","author":"P Rentzsch","year":"2021","unstructured":"Rentzsch, P., Schubach, M., Shendure, J. & Kircher, M. Cadd-splice-improving genome-wide variant effect prediction using deep learning-derived splice scores. Genome Med. 13, 31 (2021).","journal-title":"Genome Med."},{"key":"4683_CR17","unstructured":"Stata Statistical Software v. Release 18 (Stata Press, 2023)."},{"key":"4683_CR18","doi-asserted-by":"crossref","unstructured":"Weiss, F. U., Laemmerhirt, F. & Lerch, M. M. Next-generation sequencing pitfalls in diagnosing trypsinogen (Prss1) mutations in chronic pancreatitis. Gut 70, 1602\u20131604 (2021).","DOI":"10.1136\/gutjnl-2020-322864"},{"key":"4683_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/gutjnl-2021-324943","volume":"71","author":"E G\u00e9nin","year":"2022","unstructured":"G\u00e9nin, E., Cooper, D. N., Masson, E., F\u00e9rec, C. & Chen, J. M. Ngs mismapping confounds the clinical interpretation of the PRSS1 p.Ala16Val (c.47C>T) variant in chronic pancreatitis. Gut 71, 841\u2013842 (2022).","journal-title":"Gut"},{"key":"4683_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/gutjnl-2022-327203","volume":"72","author":"H Lou","year":"2023","unstructured":"Lou, H., Xie, B., Wang, Y., Gao, Y. & Xu, S. Improved Ngs variant calling tool for the PRSS1\u2013PRSS2 locus. Gut 72, 210\u2013212 (2023).","journal-title":"Gut"},{"key":"4683_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/867273","volume":"2015","author":"M Rodr\u00edguez-Cruz","year":"2015","unstructured":"Rodr\u00edguez-Cruz, M. et al. Evidence of insulin resistance and other metabolic alterations in boys with duchenne or becker muscular dystrophy. Int. J. Endocrinol. 2015, 867273 (2015).","journal-title":"Int. J. Endocrinol."},{"key":"4683_CR22","doi-asserted-by":"crossref","unstructured":"Grounds, M. D. et al. Biomarkers for duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. Dis. Model. Mech. 13, dmm043638 (2020).","DOI":"10.1242\/dmm.043638"},{"key":"4683_CR23","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","volume":"5","author":"DGS Wilson","year":"2022","unstructured":"Wilson, D. G. S., Tinker, A. & Iskratsch, T. The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction. Commun. Biol. 5, 1022 (2022).","journal-title":"Commun. Biol."},{"key":"4683_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31753-3","volume":"8","author":"J Strakova","year":"2018","unstructured":"Strakova, J. et al. Integrative effects of dystrophin loss on metabolic function of the Mdx mouse. Sci Rep 8, 13624 (2018).","journal-title":"Sci Rep"},{"key":"4683_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.dsx.2017.08.006","volume":"12","author":"C Saure","year":"2018","unstructured":"Saure, C., Caminiti, C., Weglinski, J., de Castro Perez, F. & Monges, S. Energy expenditure, body composition, and prevalence of metabolic disorders in patients with duchenne muscular dystrophy. Diabetes Metab. Syndr. 12, 81\u201385 (2018).","journal-title":"Diabetes Metab. Syndr."},{"key":"4683_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijcard.2016.12.083","volume":"230","author":"L Szablewski","year":"2017","unstructured":"Szablewski, L. Glucose transporters in healthy heart and in cardiac disease. Int. J. Cardiol. 230, 70\u201375 (2017).","journal-title":"Int. J. Cardiol."},{"key":"4683_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","volume":"128","author":"GD Lopaschuk","year":"2021","unstructured":"Lopaschuk, G. D., Karwi, Q. G., Tian, R., Wende, A. R. & Abel, E. D. Cardiac energy metabolism in heart failure. Circ. Res. 128, 1487\u20131513 (2021).","journal-title":"Circ. Res."},{"key":"4683_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s12265-023-10443-0","volume":"17","author":"S Meng","year":"2024","unstructured":"Meng, S. et al. Advances in metabolic remodeling and intervention strategies in heart failure. J. Cardiovasc. Transl. Res. 17, 36\u201355 (2024).","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"4683_CR29","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10741-021-10096-8","volume":"27","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Sglt2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Fail. Rev. 27, 961\u2013980 (2022).","journal-title":"Heart Fail. Rev."},{"key":"4683_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2023.100263","volume":"78","author":"L Fan","year":"2023","unstructured":"Fan, L. et al. Driving force of deteriorated cellular environment in heart failure: metabolic remodeling. Clinics 78, 100263 (2023).","journal-title":"Clinics"},{"key":"4683_CR31","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s00018-020-03694-6","volume":"78","author":"H Men","year":"2021","unstructured":"Men, H. et al. The regulatory roles of P53 in cardiovascular health and disease. Cell Mol. Life Sci. 78, 2001\u20132018 (2021).","journal-title":"Cell Mol. Life Sci."},{"key":"4683_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024582","volume":"11","author":"X Chen","year":"2022","unstructured":"Chen, X. et al. P53-Dependent mitochondrial compensation in heart failure with preserved ejection fraction. J. Am. Heart Assoc. 11, e024582 (2022).","journal-title":"J. Am. Heart Assoc."},{"key":"4683_CR33","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/j.celrep.2016.01.046","volume":"14","author":"L Buzaglo-Azriel","year":"2016","unstructured":"Buzaglo-Azriel, L. et al. Loss of muscle Mtch2 increases whole-body energy utilization and protects from diet-induced obesity. Cell. Rep. 14, 1602\u20131610 (2016).","journal-title":"Cell. Rep."},{"key":"4683_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/hmg\/ddac176","volume":"32","author":"JA Fischer","year":"2023","unstructured":"Fischer, J. A. et al. Opposing effects of genetic variation in Mtch2 for obesity versus heart failure. Hum. Mol. Genet. 32, 15\u201329 (2023).","journal-title":"Hum. Mol. Genet."},{"key":"4683_CR35","doi-asserted-by":"crossref","unstructured":"Tripathi, M., Yen, P. M. & Singh, B. K. Estrogen-related receptor alpha: an under-appreciated potential target for the treatment of metabolic diseases. Int. J. Mol. Sci. 21, 1645 (2020).","DOI":"10.3390\/ijms21051645"},{"key":"4683_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1530\/JME-14-0078","volume":"54","author":"J Yang","year":"2015","unstructured":"Yang, J. et al. Gemin4 functions as a coregulator of the mineralocorticoid receptor. J. Mol. Endocrinol. 54, 149\u2013160 (2015).","journal-title":"J. Mol. Endocrinol."},{"key":"4683_CR37","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00246-021-02807-7","volume":"43","author":"C Villa","year":"2022","unstructured":"Villa, C. et al. Current practices in treating cardiomyopathy and heart failure in Duchenne Muscular Dystrophy (DMD): understanding care practices in order to optimize DMD heart failure through action. Pediatr. Cardiol. 43, 977\u2013985 (2022).","journal-title":"Pediatr. Cardiol."},{"key":"4683_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03372-x","volume":"19","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt, E. et al. Predictors of cardiac disease in Duchenne muscular dystrophy: a systematic review and evidence grading. Orphanet J. Rare Dis. 19, 359 (2024).","journal-title":"Orphanet J. Rare Dis."},{"key":"4683_CR39","doi-asserted-by":"crossref","unstructured":"Wittlieb-Weber, C. A. et al. Cardiac medication use in action for Duchenne muscular dystrophy cardiomyopathy. Pediatr. Cardiol. (2025). Epub ahead of print.","DOI":"10.1007\/s00246-025-03917-2"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04683-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04683-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:34:01Z","timestamp":1791848041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04683-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":39,"alternative-id":["4683"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04683-w","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.S. has worked as a consultant for: Boerhinger Ingelheim, Capricor, Dyne, Fibrogen, Immunoforge, Sardocor and Sarepta. The other authors have no conflicts of interest or disclosures.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Consent was required from patients or their legal guardian to participate in this research study.","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}